SpringerLink
Log in

85 Pfizer Stopt Ontwikkeling Supermedicijn

  • Published:
Zorg en Financiering

Samenvatting

Onlangs heeft farmaconcern Pfizer bekendgemaakt te stoppen met de verdere ontwikkeling van het cholesterolmedicijn torcetrapib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. www.zorgenfinanciering.nl

       

Authors
  1.    
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

 ,  . 85 Pfizer Stopt Ontwikkeling Supermedicijn. ZOFI 6, 106 (2007). https://doi.org/10.1007/BF03093378

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03093378

Search

Navigation